000309927 001__ 309927
000309927 005__ 20260219134341.0
000309927 0247_ $$2doi$$a10.1016/j.ejca.2026.116256
000309927 0247_ $$2pmid$$apmid:41702246
000309927 0247_ $$2ISSN$$a0959-8049
000309927 0247_ $$2ISSN$$a0014-2964
000309927 0247_ $$2ISSN$$a1879-0852
000309927 0247_ $$2ISSN$$a(1990)
000309927 0247_ $$2ISSN$$a1879-2995
000309927 0247_ $$2ISSN$$a(1965)
000309927 037__ $$aDKFZ-2026-00377
000309927 041__ $$aEnglish
000309927 082__ $$a610
000309927 1001_ $$aEberhardt, Wilfried Ernst Erich$$b0
000309927 245__ $$aTen-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.
000309927 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2026
000309927 3367_ $$2DRIVER$$aarticle
000309927 3367_ $$2DataCite$$aOutput Types/Journal article
000309927 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771504968_3004205
000309927 3367_ $$2BibTeX$$aARTICLE
000309927 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309927 3367_ $$00$$2EndNote$$aJournal Article
000309927 500__ $$a#DKTKZFB9#
000309927 520__ $$aMore stage III non-small-cell lung cancer patients experience long-term survival (OS). ESPATUE-trial looked at surgery versus boost-radiochemotherapy following induction chemotherapy, consisting of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m2 on days 2 and 9, and concurrent vinorelbine 20 mg/m2 on days 2 and 9 (Eberhardt et al, J Clin Oncol 2015). Here, we update 10-years-OS and report competing-risks-of-deaths.Complete trial design has been published. We updated OS for patients still alive at 2/2022. Patients were followed up on a yearly basis and showed up to get follow-up imaging and reevaluation.From 1/2004 until 1/2013 246 patients medically and functionally operable were enrolled. Following induction 161 considered resectable were randomized to radiochemotherapy-boost(arm 1/A;n = 80) or definitive surgery(arm 2/B;n = 81).The median time from randomization to last evaluation was 145.1 months(interquartile range 121.5-197.8). Patients in the arm that included surgery(B) had a 10-year overall survival rate of 29.9 %(20.2-40.3) and those with radiochemotherapy(A) a rate of 28.3 %(18.8-38.5; p = 0.70 log rank). Rates of progression-free survival, death from second priomary lung cancer, death from first lung cancer, treatment related death, death from second cancer without lung cancer were comparable in both study arms CONCLUSIONS: Long-term survival serves as baseline information for ongoing immunotherapy-based stage III protocols. No significant differences between local modalities radiochemotherapy and surgery were observed. A competing-risk-of-deaths-analysis showed no relevant preference for one arm. Death from comorbidities and death from second lung cancer remain relevant long-term-risks.
000309927 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309927 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309927 650_7 $$2Other$$aCompeting risks
000309927 650_7 $$2Other$$aLong-term survival
000309927 650_7 $$2Other$$aLung cancer
000309927 650_7 $$2Other$$aMultimodality therapy
000309927 650_7 $$2Other$$aNon-small-cell
000309927 650_7 $$2Other$$aStage III
000309927 7001_ $$aSchulte, Christina$$b1
000309927 7001_ $$aPöttgen, Christoph$$b2
000309927 7001_ $$aGauler, Thomas Christoph$$b3
000309927 7001_ $$aFriedel, Godehard$$b4
000309927 7001_ $$aKopp, Hans-Georg$$b5
000309927 7001_ $$aFischer, Berthold$$b6
000309927 7001_ $$aSchmidtberger, Heinz$$b7
000309927 7001_ $$aKimmich, Martin$$b8
000309927 7001_ $$aBudach, Wilfried$$b9
000309927 7001_ $$aCordes, Sebastian$$b10
000309927 7001_ $$aMetzenmacher, Martin$$b11
000309927 7001_ $$aZaun, Gregor$$b12
000309927 7001_ $$ade Los Rios, Rodrigo Hepp$$b13
000309927 7001_ $$aSpengler, Werner$$b14
000309927 7001_ $$aBelka, Claus$$b15
000309927 7001_ $$aWelter, Stephan$$b16
000309927 7001_ $$aLuetke-Brintrup, Diana$$b17
000309927 7001_ $$aGuberina, Nika$$b18
000309927 7001_ $$aGuberina, Maja$$b19
000309927 7001_ $$aOezkan, Filiz$$b20
000309927 7001_ $$aDarwiche, Kaid$$b21
000309927 7001_ $$0P:(DE-HGF)0$$aSchuler, Martin$$b22
000309927 7001_ $$aStamatis, Georgios$$b23
000309927 7001_ $$aBölükbas, Servet$$b24
000309927 7001_ $$aHautzel, Hubertus$$b25
000309927 7001_ $$0P:(DE-HGF)0$$aStuschke, Martin$$b26
000309927 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2026.116256$$gVol. 236, p. 116256 -$$p116256$$tEuropean journal of cancer$$v236$$x0959-8049$$y2026
000309927 909CO $$ooai:inrepo02.dkfz.de:309927$$pVDB
000309927 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000309927 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000309927 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309927 9141_ $$y2026
000309927 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-11$$wger
000309927 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-11
000309927 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2025-11-11
000309927 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000309927 980__ $$ajournal
000309927 980__ $$aVDB
000309927 980__ $$aI:(DE-He78)ED01-20160331
000309927 980__ $$aUNRESTRICTED